BG Medicine stock analysis
BG Medicine (BGMD) Stock Price & Analysis
BGMD Stock Chart & Stats
- Day’s Range
- $0.02 - $0.02
- 52-Week Range
- $0.02 - $0.02
- Previous Close
- $0.02
- Volume
- N/A
- Average Volume (3M)
- 242
- Market Cap
- $1,137
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- 0.0
- Beta
- -119.17
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
BGMD FAQ
What was BG Medicine’s price range in the past 12 months?
What is BG Medicine’s market cap?
When is BG Medicine’s upcoming earnings report date?
Is BG Medicine overvalued?
Does BG Medicine pay dividends?
What is BG Medicine’s EPS estimate?
How many shares outstanding does BG Medicine have?
Which hedge fund is a major shareholder of BG Medicine?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BG Medicine
BG Medicine, Inc. is dedicated to the development and commercialization of diagnostic products aimed at guiding patient care for individuals in the United States afflicted with heart failure and related conditions. Its product portfolio includes the BGM Galectin-3 Test, an in vitro diagnostic solution that quantifies galectin-3 levels in blood serum or plasma using an enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform. Additionally, the company provides the CardioSCORE Test, a multi-analyte, biomarker-based blood test designed to assess the short-term risk of atherothrombotic cardiovascular events, such as myocardial infarction (heart attack) and ischemic stroke. BG Medicine maintains licensing, development, and commercialization agreements with major partners like Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc., specifically for automated versions of its galectin-3 test. Furthermore, it has forged a strategic alliance with Abbott Laboratories to jointly develop and market galectin-3 assay kits, along with their corresponding control kits and calibrators. Founded in 2000, the company was initially known as Beyond Genomics, Inc., before rebranding to BG Medicine, Inc. in October 2004. Its corporate headquarters are located in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Stephen Hall
- Employees
- 5
- Website
- www.bg-medicine.com
- Address
- 303 Wyman Street, Waltham, MA, 02451, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 2 | 2 |
| Technical Analysis | 2 | 0 | 0 |
| Moving Averages | 2 | 2 | 2 |

